Comparison of the Ranger™ Paclitaxel-Coated PTA Balloon Catheter and Uncoated PTA Balloons in Femoropopliteal Arteries

N/ACompletedNCT02013193

Hemoteq AG105 enrolled

Overview

The primary objective of this study is to prove the superior performance of the Ranger™ paclitaxel-coated PTA balloon catheter for angioplasty for femoropopliteal artery lesions when compared to non-coated balloons at six months post-procedure when comparing Late Lumen Loss (LLL). Study statistical hypothesis: The %-mean loss of luminal diameter as assessed by angiography at six months follow-up after treatment of the femoropopliteal artery with Ranger DCB study devices is lower than the %-mean loss of luminal diameter after treatment with uncoated PTA balloon control devices.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

105

Conditions

Peripheral Artery Disease Claudication Atherosclerosis Arteriosclerosis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects must be age 18 or older * Subject is willing and able to provide informed consent * Subject is available to attend all required follow-up visits * Subject has a clinically significant symptomatic leg ischemia requiring treatment * Subject has a Rutherford clinical category of 2-4 * If the index lesion is restenotic, the prior PTA must have been \>30 days prior to treatment in the current study * Only one lesion per limb can be treated under this protocol. * Successful intraluminal wire crossing of the target lesion * Index lesion is a clinically and hemodynamically significant stenotic or restenotic lesion located in the native nonstented superficial femoral artery or proximal popliteal artery * Degree of stenosis 70% or more, by visual assessment * Lesion length between 20 mm and 150 mm * At least one patent infrapopliteal artery to the foot of the index limb Exclusion Criteria: * Subjects who have undergone prior vascular surgery of the femoropopliteal artery in the index limb to treat atherosclerotic disease * History of major amputation in the same limb as the target lesion * Presence of aneurysm in the target vessel * Acute ischemia and/or acute thrombosis in any artery of the lower limbs * Acute Myocardial Infarction within 30 days before the index procedure * Persistent, intraluminal thrombus of the proposed target lesion post-thrombolytic therapy * Known hypersensitivity or contraindication to contrast dye that cannot be adequately pre-medicated * Known allergies against Paclitaxel or other components of the used medical devices * Intolerance to antiplatelet, anticoagulant, or thrombolytic medications that would be administered during the trial * Platelet count \<100,000 mm3 or \>600,000 mm3 * Concomitant renal failure with a serum creatinine \>2.0 mg/dL * Receiving dialysis or immunosuppressant therapy * Life expectancy of less than one year * Women of child-bearing potential must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure. * Woman who is pregnant or nursing. * Previously planned stenting of the index lesion * Use of adjunctive therapies (debulking, laser, cryoplasty, re-entry devices) * Planned or expected procedures (cardiac, aorta, peripheral) within 30 days after the index procedure * Presence of outflow lesions requiring intervention within 30 days of the index procedure * Perforated vessel as evidenced by extravasation of contrast media * Heavily calcified target lesions resistant to PTA * Current participation in another drug or device trial that has not completed the primary endpoint, that may potentially confound the results of this trial, or that would limit the subject's compliance with the follow-up requirements * Current participation in any study using drug-coated/drug-eluting technologies * Current participation in any study using drug-coated/drug-eluting technologies * Target lesion with in-stent restenosis (any stent or stent-graft)

Locations (11)

Medical University, AKH

Vienna, Austria

CHU Caen Côte de Nacre

Caen, France

Hopital Europeen Georges-Pompidou (HEGP)

Paris, France

Clinique Pasteur Toulouse

Toulouse, France

Klinikum Arnsberg

Arnsberg, Germany

Segeberger Kliniken

Bad Segeberg, Germany

Klinikum Darmstadt GmbH

Darmstadt, Germany

CardioVascular Center

Frankfurt, Germany

Universitätsklinikum Leipzig

Leipzig, Germany

Park-Krankenhaus

Leipzig, Germany

...and 1 more locations

Outcomes

Primary Outcomes

in-segment late lumen loss

In-segment late lumen loss (LLL) of the treated segment after PTA using the Ranger™ paclitaxel-coated PTA balloon, in comparison to the LLL after PTA using an uncoated balloon, as observed by angiography at six months post-index procedure.

Time frame: six months

Secondary Outcomes

technical success

The ability to cross and dilate the lesion to achieve residual angiographic stenosis no greater than 30%.

Time frame: during index procedure, less 1 hour

procedural success

Technical success with no MAE noted within 24 hours of the index procedure.

Time frame: within 24 hours of index procedure

primary patency

Percentage of lesions that reach endpoint without a hemodynamically significant stenosis on duplex ultrasound (DUS) and without target lesion revascularization (TLR) or bypass of the target lesion to maintain or restore patency.

Time frame: six months

primary patency

Percentage of lesions that reach endpoint without a hemodynamically significant stenosis on DUS and without TLR or bypass of the target lesion to maintain or restore patency.

Time frame: twelve months

assisted primary patency

Percentage of lesions without TLR and those with TLR (not due to complete occlusion or bypass) that reach endpoint without restenosis.

Time frame: six months

assisted primary patency

Percentage of lesions without TLR and those with TLR (not due to complete occlusion or bypass) that reach endpoint without restenosis.

Time frame: twelve months

secondary patency

Percentage of lesions with TLR for occlusion that reach endpoint without restenosis.

Time frame: six months

secondary patency

Percentage of lesions with TLR for occlusion that reach endpoint without restenosis.

Time frame: twelve months

binary restenosis rate

Binary restenosis defined as \> 50% diameter stenosis via peak systolic velocity ratio (PSVR) \> 2.4 via duplex ultrasound and assessed by the core lab.

Time frame: six months

binary restenosis rate

Binary restenosis defined as \> 50% diameter stenosis via peak systolic velocity ratio (PSVR) \> 2.4 via duplex ultrasound and assessed by the core lab.

Time frame: twelve months

clinical success

Positive change (by +1 or more) of Rutherford category at pre-discharge post-index-procedure as compared to baseline.

Time frame: pre-discharge, estim. 1-2 days post-index procedure

clinical success

Positive change (by +1 or more) of Rutherford category at six months (plus or minus 30 days) post-index-procedure as compared to baseline.

Time frame: six months

clinical success

Positive change (by +1 or more) of Rutherford category at twelve months (plus or minus 30 days) post-index-procedure as compared to baseline.

Time frame: twelve months

hemodynamic success

positive change in Ankle-Brachial Index (ABI) at pre-discharge as compared to baseline

Time frame: pre-discharge, estim. 1-2 days post-index procedure

hemodynamic success

positive change in ABI at six months (plus or minus 30 days) as compared to baseline

Time frame: six months

hemodynamic success

positive change in ABI at twelve months (plus or minus 30 days) as compared to baseline

Time frame: twelve months

change in quality of life

Change in functional status measured by changes in the Walking Impairment Questionnaire (WiQ) and general health-related quality of life measured by changes in SF-12 and EQ5D scores at six months (plus or minus 30 days) as compared to baseline.

Time frame: six months

change in quality of life

Change in functional status measured by changes in the Walking Impairment Questionnaire (WiQ) and general health-related quality of life measured by changes in SF-12 and EQ5D scores at twelve months (plus or minus 30 days) as compared to baseline.

Time frame: twelve months

change in quality of life

Change in general health-related quality of life measured by changes in SF-12 and EQ5D scores at 24 months (plus or minus 30 days) as compared to baseline.

Time frame: 24 months

change in quality of life

Change in general health-related quality of life measured by changes in SF-12 and EQ5D scores at 36 months (plus or minus 30 days) as compared to baseline.

Time frame: 36 months

Comparison of the Ranger™ Paclitaxel-Coated PTA Balloon Catheter and Uncoated PTA Balloons in Femoropopliteal Arteries

Overview

Conditions

Interventions

Eligibility

Locations (11)

Outcomes

Primary Outcomes

Secondary Outcomes